Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Testicular germ cell tumours, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Platinum-refractory disease has no effective therapy; checkpoint inhibitors were inactive.
Late effects of cisplatin (cardiovascular disease, second cancers, hearing loss) in men cured in their 20s.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Over-treatment of stage I disease without reliable predictors.
Access to high-dose chemotherapy and expert RPLND outside specialist centres.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Three-year progression-free survival 59 percent with marker-guided dose-dense chemotherapy against 48 percent with BEP (hazard ratio 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Updated in 2021 with LDH and age refinements.